eAnti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures  by Yaron, Michael et al.
Osteoarthritis and Cartilage (1999) 7, 272–280
? 1999 OsteoArthritis Research Society International 1063–4584/99/030272+09 $12.00/0
Article No. joca.1998.0201, available online at http://www.idealibrary.com onAnti-interleukin-1 effects of diacerein and rhein in human
osteoarthritic synovial tissue and cartilage cultures
BY MICHAEL YARON, IDIT SHIRAZI AND ILANA YARON
Arthritis Research Unit, Department of Rheumatology, Tel Aviv-Sourasky Medical Center,
Ichilov Hospital, and Tel Aviv University Sackler Faculty of Medicine
Summary
Objective: The etiology of osteoarthritis (OA) is still a matter of debate. Several factors are known to be involved in the
destruction of the articular cartilage. Interleukin-1 (IL-1) plays an important role in the pathogenesis of osteoarthritis
(OA) either directly or through the stimulation of catabolic factors, such as nitric oxide (NO). The objective of this
study was to evaluate the e#ect of diacerein, a new anti-OA agent and its active metabolite, rhein, on the production
and function of IL-1â, nitric oxide (NO) and receptor agonist (IL-1ra) in human OA cartilage and synovial tissue
cultures.
Design: Synovial tissue and cartilage derived from OA patients were kept in culture for 48–72 hours in the presence
of 1 ìg/ml of lipopolysaccharide (LPS) with or without diacerein (10"7–10"5 M), rhein (10"7–10"5 M) and hydrocor-
tisone (5 ìg/ml). IL-1â, IL-1ra, NO productions and 35S uptake were measured in culture media. In some experiments the
resulting supernatants from synovial tissue cultures were added to cartilage.
Results: Diacerein and rhein, as well as hydrocortisone, significantly inhibited LPS-induced IL-1â production by
synovial tissue and cartilage. They also significantly reversed the inhibitory e#ect of LPS on cartilage 35S uptake.
Culture media from synovial tissue containing LPS+diacerein (10"6 M) or +rhein (10"6 M) had a significantly less
inhibitory e#ect on cartilage synthesis than culture media containing LPS only. Diacerein and rhein decreased NO
release in synovial tissue and cartilage media and increased IL-1ra levels in cartilage culture media.
Conclusion: An inhibitory e#ect of diacerein and rhein at therapeutic concentrations on both IL-1â secretion and
function in human synovial tissue and cartilage is suggested. Diacerein and rhein e#ects on NO production by
LPS-stimulated OA synovial tissue and cartilage may both contribute and elucidate their anti-OA properties.
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OSTEOARTHRITIS (OA) is a slowly progressive disease
of unknown cause and obscure pathogenesis. It
is clinically characterized by pain, deformity,
enlargement of the joints, loss of joint stability and
limitation of motion. Pathologically, the disease is
characterized by focal destructive cartilage
lesions, subchondral sclerosis, cyst formation and
large osteophytes at the margins of the joint. The
disease appears to originate in the cartilage and
changes in this tissue are progressively severe
with advancing age [1]. Therapeutically, the
disorder is characterized by the lack of a specific
healing agent.
Although the etiology of OA is still a matter of
debate, several factors are known to initiate272and/or contribute to the breakdown of the articu-
lar cartilage. These include the production of
cytokines [2] and superoxide oxygen free radicals
[3], the release of proteolytic enzymes [4, 5], the
impairment of collagen and proteoglycan synthesis
[6, 7], deposition of immuno-complexes and micro-
crystals [8, 9] and synovial inflammation [10, 11].
In OA, both mechanical and enzymatic factors
are involved in cartilage matrix degradation. The
enzymatic process appears to be related to a
cascade of events with the chondrocyte being the
most important source of cartilage degradation
enzymes. The most important enzymes appear to be
metalloproteases. Collagenase and stromelysin are
the two major metalloproteases involved in
cartilage breakdown. Their levels are increased
in OA synovial fluid [12].
The regulation of chondrocytes secretory
function and their proliferation by cytokines and
growth factors is therefore central to cartilage
development and the maintenance of homeostasis
in the joint [13].
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cartilage is multifaceted and it most likely plays
an important role in the mechanism of cartilage
destruction. IL-1 suppresses the synthesis of the
cartilage matrix components, mainly collagen type
II [14] and aggregating proteoglycan (aggrecan)
[15, 16]. The ability of IL-1 to promote the degra-
dation of cartilage matrix macromolecules is
linked to its ability to promote the synthesis and
secretion of matrix proteases, including tissue
plasminogen activator, collagenase and strome-
lysin by chondrocytes [17]. The production of pros-
taglandin E2 (PGE2) by chondrocytes is also
stimulated by IL-1 [18, 19]. Overproduction of
PGE2 plays a role in exacerbating joint inflamma-
tion, stimulating bone resorption and modulating
the immune response. IL-1 inhibits chondrocyte
hypertrophy and the onset of calcification in ossi-
fying cartilage [20] and chondrocyte proliferation
induced by serum or transforming growth factor â
(TGF â) [21].
In addition to cartilage, IL-1 a#ects the function
of other articular tissues. Synovial cells also
exhibit stimulation of metalloproteases and PGE2
production in response to IL-1 [22]. IL-1 is consid-
ered a major factor of chondrocyte and synovio-
cyte activation since it induces the synthesis of
neutral metalloproteases and promotes the
destruction of macromolecules in the matrix [23]
and is amply involved in cartilage degradation and
in synovial inflammation.
Other factors implicated in the degradative pro-
cess of cartilage are also linked to cytokine
activity. Nitric oxide (NO) production is part
of the catabolic process in cartilage metabolism
and may therefore play a role in OA pathogenesis
[24, 25].
Drugs which interfere with factors known to
initiate and/or contribute to the breakdown of the
articular cartilage may provide therapeutic benefit
in the treatment of OA. Diacerein, a novel drug for
the treatment of osteoarthritis, showed anti-OA
e#ects in experimental animal OA models [26–28].
In humans, diacerein showed beneficial clinical
e#ects on the symptoms of OA patients [29, 30].
Diacerein is marketed in France by Negma as ART
50>. Diacerein is currently under evaluation as a
disease-modifying OA drug (DMOAD) in a 3-year,
randomized, double-blind, placebo-control clinical
study of 500 patients with OA of the hip
(ECHODIAH study) [31].
Diacerein has no e#ect on phospholipase A2,
cyclo-oxygenase and 5-lipoxygenase but antago-
nizes IL-1 e#ects on cartilage matrix components
and collagenolytic activity [32–35]. In other
studies diacerein and its active metabolite, rhein,have been shown to inhibit superoxide release
from human neutrophils [36] and to reduce the
migration and phagocytic activity of mouse
peritoneal macrophages [37].
The present study was designed to evaluate
in-vitro e#ects of diacerein and rhein on IL-1â,
NO and interleukin-1 receptor agonist (IL-1ra)
production in human osteoarthritic synovial and
articular cartilage cultures in order to further
elucidate their mechanism of action in OA.Materials and methodsCHEMICALS AND BIOCHEMICALS
Diacerein and rhein were dissolved in absolute
ethanol and DMSO, respectively. The final ethanol
or DMSO concentrations in experimental wells did
not exceed 0.04%. Lipopolysaccharide (LPS) at a
final concentration of 1 ìg/ml (Escherichia coli
serotype 0127: B8) was from Difco Laboratories
(Detroit, MI, U.S.A.), hydrocortisone as a water
soluble sodium succinate ester (Solu Cortef=
sterile powder) was from Upjohn s.a (Belgium),
indomethacin from Sigma (St Louis, MO, U.S.A.),
recombinant human interleukin-1â from Biogen
SA (Geneva, Switzerland). DMEM and RPMI
culture media were obtained from Biological
Industries (Beit Haemek, Israel).SPECIMEN SELECTION AND CULTURE CONDITIONS
Synovial tissue and cartilage were obtained in
the operation theater from patients undergoing
total knee or hip replacement for osteoarthritis
(11 males, age 66.8&6.7 years; 17 females, age
70.4&1.4 years, mean&SD).Organ cultures
Within 2 hours of removal, synovial tissues were
cut into small pieces, a few millimeters in diameter
and approx. 80 mg synovial tissue pieces were
cultured in 2 ml RPMI 1640 supplemented with
L-glutamine (2 mM), penicillin (100 U/ml) and
streptomycin sulphate (100 ìg/ml) (Biological
Industries) with test materials. Following 48 hours
of incubation (37)C, 5% CO2), the measurement of
IL-1â, nitric oxide (NO) and IL-1ra production was
performed in supernates.
Cartilage tissue (without distinction between
‘normal’ and diseased areas) was finely diced,
randomized and distributed in 96-well plates con-
taining approx. 15 mg cartilage pieces per well in
0.2 ml DMEM, 1% FCS, penicillin and strepto-
mycin. Test materials were added and followed 24
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Buckinghamshire, U.K., specific activity
1100 Ci/mmol) at a final concentration of
40 ìCi/ml. After two days of further incubation
the supernates and cartilage were collected for
35S-glycosaminoglycan (35S-GAG) determination.
IL-1â, IL-1ra and NO assays were performed in
separate cultures with no radioactive material
added (after 48 hours incubation).35S-GAG determination
Labeled 35S-GAG was determined in proteolytic
digests of combined cartilage tissue and culture
medium by the cetyl pyridinium chloride fixation
wash procedure [38, 39]. Digestion was performed
at 55)C for 16 hours with pronase (0.5 mg/ml) in
0.05 M Tris bu#er pH 7.6 (Sigma, St Louis, MO) in
a total volume of 300 ìl.
Experiments on cartilage were performed either
with test materials added directly to cartilage
culture or, as described in the legend of Fig. 4,
drugs were added to synovial tissue cultures, incu-
bated for two days and the resulting supernatants
added to cartilage cultures. Untreated synovial
tissue media (conditioned media) obtained in the
same way were used as controls.Interleukin-1â, interleukin-1 receptor antagonist
and nitric oxide production determination
IL-1â and IL-1ra secreted into culture media
were determined by quantikine human immuno-
assay technique (R&D Systems, Inc., U.S.A.),
which uses the quantitative sandwich enzyme
immunoassay technique. Detection limits were
1 pg/ml and 14 pg/ml, respectively.
NO was determined as previously described by
Ashab et al. [40]: NO2 and NO3 were determined
after the reduction of NO3 to NO2 by a 90 min
incubation in a tilting bath (37)C) using nitrate
reductase from E. coli and beta nicotinamide
adenine dinucleotide phosphate (reduced form)
(Sigma) as cofactor. NO2 was determined with
Griess reagent. Sensitivity of procedure was 3 ìM.Cell viability determination
Cell viability in the presence of diacerein and
rhein (10"5–10"7 M) was performed on human
synovial fibroblast monolayer cultures after drug
exposure for 72 h by trypan blue exclusion test.
Toxicity was evaluated by tritiated thymidine
incorporation into DNA.Calculation and statistical analysis
In synovial tissue and articular cartilage cul-
tures, results of IL-1â, IL-1ra and NO determina-tions were expressed per mg tissue using tissue
weights obtained at the end of experiments.
In general, results were verified in at least three
experiments, each performed in triplicate or quad-
ruplicate. In most cases data from a representative
experiment are shown. However, where there was
some variability between experiments, results from
several experiments were pooled and expressed as
percentage (Figs 6, 7). Statistical significance
(P-determination) was evaluated by ANOVA and
by a Student’s t-test. A P-value less than 0.05 was
considered statistically significant.FIG. 1. E#ect of diacerein (D) (10"6 M), rhein (R)
(10"6 M), hydrocortisone (hydro) (5 ìg/ml) and
indomethacin (indo) (5 ìg/ml) on IL-1â secreted by LPS
stimulated human synovial tissue in culture. P-values
(versus LPS) were as follows: *P<0.05, **P<0.02,
***P<0.001.Results
In a typical experiment (Fig. 1), the e#ects
of diacerein (10"6 M), rhein (10"6 M), hydrocorti-
sone (10"5 M) and indomethacin (10"5 M) on IL-1â
secretion were investigated on human OA synovial
tissue in culture with and without LPS (1 ìg/ml).
In the absence of LPS, IL-1â levels in control
culture media were low (21 pg/ml); test materials
without LPS did not show significant changes
compared to controls (Fig. 1). LPS added to cul-
tures induced a 47-fold increase of IL-1â produc-
tion by human OA synovial tissue. Both diacerein
and rhein induced a significant inhibition of IL-1â
production stimulated by LPS. Hydrocortisone
and indomethacin also had an inhibitory e#ect in
this respect, and only reached a statistical
significance for hydrocortisone (Fig. 1).
In cultured human cartilage (Fig. 2), the e#ects
of diacerein and rhein (10"7 to 10"5 M) on IL-1â
secretion was assessed in the presence or the
absence of LPS. Without LPS, IL-1â was poorly
produced by cartilage and was amply secreted
when LPS (1 ìg/ml) was added to cultures (Fig. 2).
Osteoarthritis and Cartilage Vol. 7 No. 3 275In these conditions, diacerein and rhein induced
a dose-dependent decrease of IL-1â production
stimulated by LPS in cultured human cartilage
with statistical significance at 10"6 and 10"5 M.
The e#ect of three concentrations of rhein on
proteoglycan synthesis was studied in human car-
tilage in culture (Fig. 3). LPS (1 ìg/ml) induced a
remarkable decrease of 35S incorporation by
cartilage. Rhein significantly reversed, in a dose-
dependent manner, this inhibition and counter-
acted the inhibitory e#ect of LPS on the
proteoglycan synthesis. Diacerein at equivalent
concentrations was 89&24% as e#ective as rhein
in reversing inhibition (data not shown).
The influence of conditioned media from human
OA synovial tissue, kept in culture, on 35S incor-
poration by cultured cartilage was assessed
(Fig. 4). Conditioned media from synovial tissue
cultured in the presence of LPS for 72 hours
inhibited 35S incorporation into human articular
cartilage (N=4) (Fig. 4). The presence of diacerein
(10"6 M), rhein (10"6 M) or hydrocortisone(10"5 M) with LPS in human OA synovial media
significantly reversed the inhibitory e#ect of con-
ditioned media with LPS alone on 35S uptake by
human cartilage cultures (Fig. 4).
The e#ects of diacerein and rhein on NO concen-
tration in culture media of human synovial tissue
and human articular cartilage are presented in
Figs 5, 6. LPS (1 ìg/ml) added to the culture media
induced a 27% and 200% increase of the NO
production in synovial tissue and cartilage cul-
tures, respectively. Diacerein and rhein decreased
LPS stimulated NO concentrations in both cul-
tures. Inhibition was statistically significant at
10"5 M drug concentration.FIG. 2. E#ect of diacerein (D) and rhein (R) (10"7–
10"5 M) on IL-1â secreted by LPS stimulated human
cartilage in culture. Significance was versus LPS:
*P<0.05.FIG. 3. E#ect of rhein (R) (10"7–10"5 M) on LPS inhibi-
tion of human cartilage 35S-GAG synthesis. Significance
was versus LPS: *P<0.05, ***P<0.0001.FIG. 4. E#ects of synovial tissue media on 35S uptake by
human cartilage cultures. Drugs were added to synovial
cell tissue cultures, incubated for two days and the
resulting supernatants (conditioned media=CM) added
to cartilage cultures either alone or with LPS and no
test materials (CM-LPS), with LPS and diacerein
(C"LPS+D), with LPS and rhein (CM"LPS+R), with
LPS and hydrocortisone (CM–LPS+hydro). P-values
(versus LPS) were: **P<0.02, ***P<0.001.FIG. 5. E#ect of diacerein (D) (10"5 M) and rhein (R)
(10"6 and 10"5 M) on nitric oxide (NO) release into the
media of LPS stimulated human synovial tissue in cul-
ture. Significance versus LPS was: *P<0.05, **P<0.002.
NO represents combined measurements of NO3 and NO2
as described in Materials and Methods.
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studied in synovial tissue and cartilage cultures
(Figs 7, 8). In both cultures, LPS (1 ìg/ml) stimu-
lated the IL-1ra concentration in the medium.
Diacerein and rhein significantly inhibited IL-1ra
released in synovial culture media (Fig. 7), but
stimulated its concentration in media of human
cartilage cultures (Fig. 8).
Diacerein and rhein, added to synovial fibroblast
monolayer cultures at concentrations of 10"6 and
10"5 M did not show any deleterious e#ect on cell
viability which remained >90% in comparison
with controls.FIG. 6. E#ect of diacerein (D) and rhein (R) (10"6 and
10"5 M) on NO levels in media of LPS stimulated human
articular cartilage cultures. Results are expressed ver-
sus a 100% LPS stimulated human cartilage culture for
four independent experiments. Mean absolute values
were for control 6.3 ìM/mg cartilage and for LPS
19.8 ìM/mg cartilage. Significance versus LPS was:
*P<0.05, ***P<0.001.FIG. 7. E#ect of diacerein (D) (10"6 and 10"5 M) and
rhein (R) (10"6 M) on interleukin-1 receptor antagonist
(IL-1ra) in synovial tissue cultures. Results are
expressed versus a 100% LPS stimulated human syno-
vial tissue culture for four independent experiments.
Mean absolute values were for control 117 pg/mg syno-
via and for LPS 434 pg/mg synovia. Significance versus
LPS was: **P<0.02, ***P<0.001.FIG. 8. E#ect of diacerein (D) and rhein (R) (10"6 and
10"5 M) on interleukin-1 receptor antagonist (IL-1ra)
secreted into the media of LPS stimulated human articu-
lar cartilage. Significance versus LPS was: *P<0.05,
**P<0.002, ***P<0.001.Discussion
The e#ects of diacerein and rhein on IL-1â,
IL-1ra and NO production in human OA synovial
and cartilage cultures and their action on carti-
lage proteoglycan synthesis in the presence of an
IL-1 inducer (LPS) are reported in this study.
Experiments were performed in an in-vitro model
using in some of them a combination of human
synovial tissue media and human articular carti-
lage cultures in order to mimic in part the in-vivo
situation. The objective of this study was to clarify
the mechanism of action of diacerein and rhein on
human OA cartilage.
IL-1 is one of the important factors involved in
cartilage destruction in osteoarthritis. The pres-
ence of both IL-1Æ and IL-1â in OA synovium and
cartilage has been documented and previously
reported using immunohistochemical techniques
[41, 42]. Since IL-1 can induce resorption of carti-
lage [43], it is tempting to presume that its involve-
ment in the etiology of OA very likely, but the
precise cascade of events resulting in cartilage
damage is yet to be clarified. However, much
evidence suggests that IL-1 can modulate chondro-
cyte metabolism, including synthesis of matrix
macromolecules and proteases.
In our model, diacerein and rhein did not exhibit
any e#ect on IL-1â production in the absence of
LPS. LPS is considered to promote inflammation
[44], probably by stimulating production of
cytokines such as IL-1 and TNFÆ [45]. When syn-
ovium and cartilage were treated with LPS, IL-1â
production was induced. Diacerein and rhein
significantly inhibited this stimulation of IL-1â
production at therapeutic doses. This confirms the
findings of Pelletier et al indicating that diacerein
and its metabolite, rhein, inhibited the synthesis of
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inhibitory e#ect of LPS on cartilage 35S-GAG syn-
thesis (Figs 3, 4), which may be related to their
inhibition of IL-1 production.
Both drugs, as well as hydrocortisone, lowered
IL-1â levels in LPS-stimulated synovial condi-
tioned media and reversed the inhibitory e#ect of
synovial conditioned media on cartilage matrix
synthesis.
IL-ra is a protein produced by several cell types,
including monocytes, synoviocytes and chondro-
cytes, and is able to block several of the e#ects of
IL-1 [47]. In our experiments, LPS stimulated the
production of IL-1ra in synovial tissue and carti-
lage cultures, as reported in a previous study [48].
Its stimulated secretion in the media of human
cartilage cultures induced by diacerein and rhein
may explain at least in part the beneficial e#ects of
these drugs on cartilage matrix constituents in
OA. Our results are consistent with those of Caron
et al. who demonstrated that intra-articular injec-
tions of recombinant human IL-1 receptor antag-
onist can protect against the development of OA
lesions by a reduction of collagenase expression
[49]. An intriguing finding described in Figs 7 and
8 is that rhein and diacerein significantly inhibit
LPS induced IL-1ra production in OA synovial
tissue cultures, while they significantly stimulate
it in OA articular cartilage cultures. In addition,
the amount of IL-1ra produced by 1 mg synovial
tissue (117 pg/mg synovia and LPS stimulated
434 pg/mg synovia, see legend to Fig. 7) is much
higher than that produced by 1 mg cartilage in
culture (1 and 3 pg/mg cartilage, respectively, see
Fig. 8). However, in early osteoarthritis the total
amount of cartilage is much larger than that of the
synovial membrane. This could suggest that at
least from the point of view of their e#ect on IL-1ra
production, rhein and diacerein would be more
e#ective in early OA when the total mass of carti-
lage is much larger than that of synovial tissue.
Furthermore, the local increased production of
IL-1ra induced by diacerein and rhein in cartilage
may be more important than the altered produc-
tion of IL-1ra occurring in synovial tissue. In the
same vein, results in Fig. 4 point out that condi-
tioned media of synovial tissue in the presence of
LPS and diacerein reverse inhibition of cartilage
synthesis induced by LPS alone, in spite of stimu-
lated IL-1ra in synovial tissue conditioned media.
In OA, the primary lesion a#ects the cartilage,
while synovial inflammation is secondary and
likely related to the action of several factors,
including the release of cartilage matrix break-
down products and the presence of microcrystals
in the synovial fluid and in the synovium [1, 50].Diacerein and rhein induced an inhibition of both
IL-1â and IL-1ra in the synovial tissue culture,
while in cartilage culture, these agents inhibited
IL-1â, counteracted the inhibitory e#ects of this
cytokine on the 35S-GAG synthesis and stimulated
the production of IL-1ra. Considering these find-
ings, the net e#ect of rhein and diacerein on the
cartilage, which is the primary location of OA
lesions, is beneficial. This is confirmed in di#erent
animal models of OA, where diacerein adminis-
tered to animals exhibited chondroprotective
activities [26–28].
Diacerein can have e#ects at the level of
gene expression [51], translation and/or post-
translation [46]. In a recent experiment, diacerein
and rhein e#ects on IL-1â were found to be post-
transcriptional by the absence of an e#ect on gene
expression [46]. In the same study, the authors
demonstrated that both drugs produced a decrease
in the number of IL-1 receptors on OA chondro-
cytes: this is of importance because an increase in
the number of IL-1 receptors per cell was reported
in OA chondrocytes and synoviocytes, thus
rendering human OA cartilage matrix synthesis
sensitive to inhibition by IL-1 [52]. These findings
together with the ability of diacerein and rhein to
stimulate IL-1ra in cartilage culture may explain
why diacerein also has an inhibitory action on IL-1
function in cartilage.
Increased levels of NO have been found in OA
and rheumatoid arthritis human synovial fluid
[53]. Synovial cells and chondrocytes are import-
ant sources of NO production [54, 55]. Its synthesis
by chondrocytes and synoviocytes is stimulated by
inflammatory cytokines such as IL-1 and TNF-Æ
[56] and also by LPS [24]. In our study, both
diacerein and rhein inhibited the production of
NO after LPS stimulation of synovial tissue and
cartilage cultures. Although its production is
stimulated by cytokines, it might play a role, itself,
by mediating IL-1 proteoglycan synthesis suppres-
sion in articular cartilage [16] and by reducing the
synthesis of IL-1ra [57]. These observations stress
the important role of NO as a mediator of the
pathophysiological changes taking place in OA.
Inhibition of its synthesis by diacerein and rhein
may contribute to the beneficial role of diacerein
in OA. Although IL-1 plays a central role in the
development and perpetuation of OA, there are
close interrelations between factors acting in the
disease [58]. The pathophysiology of arthrosis is
still not clearly elucidated due to the high com-
plexity of the regulations involved in joint home-
ostasis. However the inhibition of one or more of
these factors involved in cartilage breakdown,
could decrease the lesions of cartilage, bone and
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the experimental animal models of OA [26–28]. The
e#ects of rhein and diacerein observed in our
experiments were at concentrations devoid of cell
toxicity and close to human therapeutic doses. In
humans, the maximum plasma concentration of
diacerein was 11 ìM after a single dose of 50 mg
diacerein [59]. Following a daily administration of
50 mg diacerein every 12 hours for one month,
rhein was found in the synovial fluid at concen-
trations in the 1–10 ìM plasma range (personal
communication). This confirms that the active
compound of diacerein, rhein, was used in the
present study at levels which demonstrated phar-
macological activities in both in-vivo and in-vitro
models. In the present study, activity was found for
both the prodrug and active metabolite, as has
been reported in other in-vitro studies [32, 35, 36].
Whether this is due to in-vitro conversion of
diacerein to rhein or to in-vitro biological activity
residing in chemical structures common to both
molecules is not known.
In conclusion, diacerein and rhein significantly
inhibit IL-1â production and function in human
osteoarthritic synovial membrane and cartilage
cultures and therefore may inhibit deleterious
e#ects of IL-1â in OA. Their e#ects on IL-1ra and
NO produced in human articular cartilage may
also play a beneficial role in this respect. These
pharmacological activities of diacerein, observed
at doses devoid of cell toxicity and close to human
therapeutic doses, contribute to clarification of the
mechanisms of action of diacerein which are
directly related to the protection of human
osteoarthritic human cartilage.References
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